Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show
Spring on the Road
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Intersect Ent Inc
(NQ:
XENT
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, May 12, 2022
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Intersect Ent Inc
Real-World Evidence Study Demonstrates Intersect ENT’s PROPEL® Sinus Implant Reduces Healthcare Resource Utilization
January 25, 2022
From
Intersect ENT, Inc.
Via
Business Wire
Intersect ENT Reports Third Quarter 2021 Financial Results
November 02, 2021
From
Intersect ENT, Inc.
Via
Business Wire
First Implants of PROPEL® Contour in Patients with Chronic Rhinosinusitis Following Frontal Sinus Surgery in Europe
October 28, 2021
From
Intersect ENT®, Inc.
Via
Business Wire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates INOV, LMRK, XENT, JAX; Shareholders are Encouraged to Contact the Firm
September 13, 2021
NEW YORK, NY / ACCESSWIRE / September 13, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Inovalon Holdings, Inc. (NASDAQ: INOV)...
From
Halper Sadeh LLP
Via
AccessWire
Topics
Fraud
Exposures
Legal
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates INOV, GTS, XONE, XENT; Shareholders are Encouraged to Contact the Firm
September 04, 2021
NEW YORK, NY / ACCESSWIRE / September 4, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Inovalon Holdings, Inc. (NASDAQ:INOV)...
From
Halper Sadeh LLP
Via
AccessWire
Topics
Fraud
Exposures
Legal
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates CSOD, XENT, FFWM, RIVE; Shareholders are Encouraged to Contact the Firm
August 19, 2021
NEW YORK, NY / ACCESSWIRE / August 19, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Cornerstone OnDemand, Inc. (NASDAQ:CSOD)...
From
Halper Sadeh LLP
Via
AccessWire
Topics
Fraud
Exposures
Legal
INVESTIGATION: Halper Sadeh LLP Investigates NLOK, XENT, NWHM; Shareholders are Encouraged to Contact the Firm
August 12, 2021
NEW YORK, NY / ACCESSWIRE / August 12, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: NortonLifeLock Inc. (NASDAQ:NLOK) concerning...
From
Halper Sadeh LLP
Via
AccessWire
Topics
Fraud
Exposures
Legal
INTERSECT ENT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Intersect ENT - XENT
August 06, 2021
From
Kahn Swick & Foti, LLC
Via
Business Wire
Intersect ENT Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Intersect ENT, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – XENT
August 06, 2021
From
Halper Sadeh LLP
Via
Business Wire
Intersect ENT Reports Second Quarter 2021 Financial Results
August 06, 2021
From
Intersect ENT, Inc.
Via
Business Wire
U.S Nationwide Commercial Availability of the VenSure™ Balloon Sinus Dilation System and Cube™ Navigation System Highlight Intersect ENT’s Continued Commitment to Providing Innovative, Solutions for Patients with Chronic Rhinosinusitis
July 26, 2021
From
Intersect ENT
Via
Business Wire
Intersect ENT to Report Second Quarter 2021 Financial Results on August 6
July 23, 2021
From
Intersect ENT, Inc.
Via
Business Wire
Intersect ENT Announces Preliminary Revenue for Second Quarter of 2021 and Closing of $60 Million Term Loan
July 22, 2021
From
Intersect ENT, Inc.
Via
Business Wire
Intersect ENT Receives CE Mark Approval for PROPEL® Contour for Patients with Chronic Rhinosinusitis Following Frontal Sinus Surgery
May 20, 2021
From
Intersect ENT, Inc.
Via
Business Wire
Intersect ENT Reports First Quarter 2021 Financial Results
May 10, 2021
From
Intersect ENT, Inc.
Via
Business Wire
Intersect ENT to Participate at Upcoming Investor Conferences
May 07, 2021
From
Intersect ENT, Inc.
Via
Business Wire
Intersect ENT Announces Appointment of New Vice President of Sales
May 04, 2021
From
Intersect ENT, Inc.
Via
Business Wire
Intersect ENT Announces Date Change for First Quarter 2021 Financial Results Announcement
April 29, 2021
From
Intersect ENT, Inc.
Via
Business Wire
EXPAND Post-Market Study Evaluating Longer-Term Outcomes of PROPEL® Contour Sinus Implant in the Frontal Sinus Ostia Following In-Office Balloon Sinus Dilation
April 29, 2021
From
Intersect ENT, Inc.
Via
Business Wire
Intersect ENT to Report First Quarter 2021 Financial Results
April 20, 2021
From
Intersect ENT, Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.